Premium Nahrungsergänzungsmittel | artgerecht

JAK Inhibitors: Mechanism, Uses & Side Effects

JAK inhibitors are prescription medications that selectively block Janus kinases, reducing inflammation in conditions such as rheumatoid arthritis and atopic dermatitis.

Regular tips about health Regular tips about health

Things worth knowing about "JAK inhibitors"

JAK inhibitors are prescription medications that selectively block Janus kinases, reducing inflammation in conditions such as rheumatoid arthritis and atopic dermatitis.

What Are JAK Inhibitors?

JAK inhibitors (Janus kinase inhibitors) are a class of medications that selectively block enzymes known as Janus kinases (JAK). These enzymes play a key role in transmitting inflammatory signals within the body. By inhibiting them, JAK inhibitors can reduce the overactive immune response seen in many chronic inflammatory and autoimmune diseases. They belong to a group called targeted synthetic DMARDs (disease-modifying antirheumatic drugs).

Mechanism of Action

The human body contains four Janus kinases: JAK1, JAK2, JAK3, and TYK2. These enzymes are part of the JAK-STAT signaling pathway, through which many cytokines (immune messenger molecules) exert their effects. When cytokines bind to cell surface receptors, they activate JAK enzymes, which in turn phosphorylate STAT proteins. These then migrate to the cell nucleus and regulate gene expression, including the production of further inflammatory mediators.

JAK inhibitors bind to the active sites of these enzymes, blocking their activity. Different drugs target different JAK subtypes, which explains the varying indications and side effect profiles across the drug class.

Approved Substances and Indications

Several JAK inhibitors are currently approved in the EU and internationally. The most important include:

Tofacitinib: Approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and juvenile idiopathic arthritis (inhibits JAK1 and JAK3).
Baricitinib: Approved for rheumatoid arthritis, atopic dermatitis, and alopecia areata (inhibits JAK1 and JAK2).
Upadacitinib: Approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, and Crohn's disease (selective JAK1 inhibitor).
Filgotinib: Approved for rheumatoid arthritis (selective JAK1 inhibitor).
Ruxolitinib: Approved for myelofibrosis, polycythemia vera, and atopic dermatitis (topical formulation) (inhibits JAK1 and JAK2).
Deucravacitinib: Selective TYK2 inhibitor approved for moderate to severe plaque psoriasis.

Areas of Use

JAK inhibitors are used in a wide range of chronic inflammatory and autoimmune conditions, including:

Rheumatoid arthritis (RA)
Psoriatic arthritis
Atopic dermatitis (eczema)
Ulcerative colitis and Crohn's disease
Alopecia areata
Ankylosing spondylitis
Myelofibrosis and polycythemia vera (hematological conditions)

Dosage and Administration

Most oral JAK inhibitors are taken as tablets, typically once or twice daily. The exact dosage depends on the specific drug, the indication, and individual patient factors such as kidney function. Some JAK inhibitors are also available as topical formulations (e.g., cream or ointment) for skin conditions. Treatment should always be supervised by a qualified healthcare professional.

Side Effects

JAK inhibitors can cause a range of side effects. Commonly reported adverse effects include:

Infections: Increased risk of bacterial, viral (including herpes zoster), and opportunistic infections
Blood count changes: e.g., anemia, neutropenia, thrombocytopenia
Elevated liver enzymes (transaminase increase)
Lipid changes: Increases in LDL and HDL cholesterol
Gastrointestinal complaints: Nausea, diarrhea
Increased risk of major adverse cardiovascular events (MACE) in certain risk groups
Increased malignancy risk: Particularly in older patients and smokers
Thromboembolic events: Deep vein thrombosis, pulmonary embolism (especially at higher doses)

Due to these safety signals, the European Medicines Agency (EMA) has restricted the use of JAK inhibitors in certain high-risk patient groups and issued additional warnings.

Contraindications and Precautions

JAK inhibitors are not suitable for all patients. Special caution is warranted in:

Active or chronic infections (e.g., tuberculosis, hepatitis)
Severe renal or hepatic impairment
Pregnancy and breastfeeding (contraindicated)
Patients over 65 years of age with additional risk factors (cardiovascular, malignancy, smoking)
Existing or prior malignancies

JAK Inhibitors Compared to Biologics

Unlike biologics (e.g., TNF inhibitors, IL-6 blockers), which are administered by injection or infusion and target individual cytokines, JAK inhibitors are taken orally and act intracellularly on multiple signaling pathways simultaneously. This offers practical advantages in terms of administration, but requires careful consideration of the benefit-risk profile, particularly regarding safety.

References

Smolen JS et al. - Rheumatoid arthritis. Nature Reviews Disease Primers, 2018. DOI: 10.1038/nrdp.2018.1
European Medicines Agency (EMA) - JAK inhibitors: new measures to minimise risk of serious side effects. EMA/PRAC, 2023. Available at: https://www.ema.europa.eu
Virtanen AT et al. - Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs, 2019. DOI: 10.1007/s40259-019-00362-9

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.